Dr. Moskowitz on the ALCANZA Trial in CTCL

4 Visninger
administrator
administrator
08/09/23

Alison J. Moskowitz, MD, clinical director, Lymphoma Inpatient Unit, Memorial Sloan Kettering Cancer Center, discusses the data that led to the approval of brentuximab vedotin (Adcetris) in patients with cutaneous T-cell lymphoma (CTCL).

  • Kategori

Vis mere
0 Kommentarer Sorter efter

    Ingen kommentarer fundet

    Facebook kommentarer

    Næste

    Episode 14 - Ewing Sarcoma Phase 3 Clinical Trial - Discussing The Results
    00:46:23
    Episode 14 - Ewing Sarcoma Phase 3 Clinical Trial - Discussing The Results
    administrator
    5 Visninger
    Cancer ‘cured’ in all patients in drug trial, Indian origin patient healed
    00:05:44
    Cancer ‘cured’ in all patients in drug trial, Indian origin patient healed
    administrator
    2 Visninger
    BroMac Trial: US perspective: Dr. Edward Levine, Chief of Surgical Oncology, Wake Forest
    00:11:41
    BroMac Trial: US perspective: Dr. Edward Levine, Chief of Surgical Oncology, Wake Forest
    administrator
    2 Visninger
    BroMac Trial: US perspective: Dr. Edward Levine, Chief of Surgical Oncology, Wake Forest
    00:11:41
    BroMac Trial: US perspective: Dr. Edward Levine, Chief of Surgical Oncology, Wake Forest
    administrator
    1 Visninger
    Do People of Color Have an Earlier Onset of CTCL? (Chapter 8)
    00:03:06
    Do People of Color Have an Earlier Onset of CTCL? (Chapter 8)
    administrator
    3 Visninger
    CTCL Presentation Varies Widely Among Patients, Even Within Subtypes
    00:02:51
    CTCL Presentation Varies Widely Among Patients, Even Within Subtypes
    administrator
    2 Visninger
    The Importance of Collaboration in Treating CTCL (Chapter 7)
    00:02:30
    The Importance of Collaboration in Treating CTCL (Chapter 7)
    administrator
    3 Visninger
    The CTCL diagnosis journey
    00:00:20
    The CTCL diagnosis journey
    administrator
    6 Visninger
    Unmet needs for late-stage CTCL
    00:01:10
    Unmet needs for late-stage CTCL
    administrator
    3 Visninger
    Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL
    00:01:16
    Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL
    administrator
    2 Visninger
    Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL
    00:01:35
    Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL
    administrator
    4 Visninger
    FDA Approvals in CML, CTCL, CMV Infection, and Tumor Assay, and Clinical Holds Lifted
    00:08:49
    FDA Approvals in CML, CTCL, CMV Infection, and Tumor Assay, and Clinical Holds Lifted
    administrator
    10 Visninger
    Pre-clinical activity of tipifarnib in CTCL
    00:02:12
    Pre-clinical activity of tipifarnib in CTCL
    administrator
    5 Visninger
    Cerdulatinib yields 'encouraging' results in CTCL, PTCL
    00:04:47
    Cerdulatinib yields 'encouraging' results in CTCL, PTCL
    administrator
    3 Visninger
    CTCL 06 2017
    02:28:08
    CTCL 06 2017
    administrator
    2 Visninger
    Brentuximab vedotin for CTCL
    00:02:30
    Brentuximab vedotin for CTCL
    administrator
    2 Visninger
    Clonal evolution in patients with CTCL
    00:02:24
    Clonal evolution in patients with CTCL
    administrator
    3 Visninger
    RESMAIN: HDAC inhibitor resminostat for CTCL
    00:01:23
    RESMAIN: HDAC inhibitor resminostat for CTCL
    administrator
    1 Visninger
    Etiopathogenesis of CTCL for dermatology residents I Dr.P.Ram Sushruth
    00:13:18
    Etiopathogenesis of CTCL for dermatology residents I Dr.P.Ram Sushruth
    administrator
    2 Visninger